Clinical trials: Steatosis
Fatty Liver
Evaluate Patients With Chronic Hepatitis by Three-dimensional Force-controlled Ultrasound Measurement
Ultrasound (US) B mode image is an alternative method to measure tissue structure and has proven to be an accurate technique to measure subcutaneous fat thickness.
- Trial name
- NCT02784925
- Testing
- Ultrasound (US) B mode image
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University WanFang Hospital
Non-alcoholic Fatty Liver Disease, NAFLD
Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease
There is a significant association between autonomic dysfunction and symptoms experienced by NAFLD patients mediated by increased systemic inflammation and insulin resistance, resulting in deteriorating quality of life of…
- Conditions
- Non-alcoholic Fatty Liver Disease, NAFLD, Fatty Liver, Nonalcoholic, Nonalcoholic Fatty Liver Disease
- Trial name
- AD-NAFLD (NCT02132780)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Virginia Commonwealth University
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), MetALD
Personalized Dietary Feedback to Reduce Hepatic Steatosis in Patients With MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD) and combined metabolic dysfunction and alcohol-associated liver disease (MetALD) are common chronic liver diseases associated with metabolic dysfunction and an…
- Conditions
- MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), MetALD, Steatotic Liver Disease
- Trial name
- PERSOMA (NCT07914829)
- Testing
- Personalized Dietary Feedback, Generic Dietary Feedback
- Where
- Austria
- Volunteers
- 174 people
- Sponsor
- Medical University of Vienna
Diabetes Mellitus Type 2, Dyslipidemia
Low Calorie Diet and Diabetes
The primary hypothesis is to investigate whether a low calorie diet for 7 weeks followed by continuous lifestyle advice is an effective option to achieve an improvement in glucose control as measured by HbA1c after 52 and 104…
- Conditions
- Diabetes Mellitus Type 2, Dyslipidemia, Non-alcoholic Fatty Liver Disease, Obesity
- Trial name
- LCD (NCT02498990)
- Testing
- Low calorie diet followed by life style intervention
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Karolinska University Hospital
Fatty Liver Disease, Chronic Glomerular Disease
Metabolic Associated Fatty Liver Disease in Patients With Chronic Glomerular Disease
The association of metabolic associated fatty liver disease in patients with chronic glomerular disease
- Trial name
- NCT06691529
- Volunteers
- 500 people
- Sponsor
- Assiut University
Healthy Volunteers, Hepatic Steatosis
First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases
This study will assess the safety, tolerability, the pharmacokinetics from single injection (under the skin) of NNC0581-0001 and explores the pharmacodynamics in healthy participants and participants with hepatic steatosis…
- Trial name
- NCT05599945
- Testing
- NNC0581-0001
- Where
- 2 sites in United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
NAFLD
Ketohexokinase Inhibition in NAFLD
Fructose is a big contributor to the development of non-alcoholic fatty liver disease (NAFLD). Inhibiting ketohexokinase (KHK), the enzyme catalyzing the first committed step in fructose metabolism, is thought to reduced…
- Trial name
- KHKi (NCT05463575)
- Testing
- Ketohexokinase inhibition
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Postprandial Lipids Metabolism, Type 2 Diabetes
Combined Nutritional and Exercise Strategies to Reduce Liver Fat Content in Patients With Type 2 Diabetes
The aim of this study will be to evaluate in patients with type 2 diabetes the effects on liver fat of an intervention with a diet relatively rich in CHO/rich in fibre/low GI or a diet rich in MUFA, either combined or not with a…
- Trial name
- NCT01025856
- Testing
- Rich in MUFA diet -PA, high fiber/low glycemic index diet + pa, Rich in MUFA diet+PA
- Volunteers
- 45 people
- Sponsor
- Federico II University
Nonalcoholic Fatty Liver Disease, NAFLD
Rifaximin in Fatty Liver Disease
TITLE Rifaximin in Fatty Liver Disease (RiFL) DESIGN Open-label pilot study HYPOTHESIS Reduction in gut flora by the antibiotic Rifaximin reduces hepatic inflammation in Non-Alcoholic Steatohepatitis (NASH).
- Conditions
- Nonalcoholic Fatty Liver Disease, NAFLD, Nonalcoholic Steatohepatitis
- Trial name
- RiFL (NCT01355575)
- Testing
- Rifaximin
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Imperial College London
Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease
Diabetes, Exercise and Liver Fat (DELIVER)
This randomised controlled trial will determine if exercise (150 - 200 min per week, 6 weeks) can beneficially modify liver fat quality in non alcohol fatty liver disease patients with type 2 diabetes mellitus (n = 26, 13 per…
- Conditions
- Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, Obesity, Insulin Resistance
- Trial name
- (DELIVER) (NCT04004273)
- Testing
- Exercise
- Where
- 4 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- James King
NAFLD
Comparison of Two sTRAtegies For the Non-Invasive Diagnosis of advanCed Liver Fibrosis in NAFLD
NAFLD, closely linked to overweight and insulin resistance, has reached 25% prevalence worldwide. Advanced liver fibrosis(ALF) must be accurately diagnosed in NAFLD because it defines a subgroup of patients with impaired…
- Trial name
- TRAFIC (NCT04681573)
- Testing
- blood tests
- Where
- 20 sites in France
- Volunteers
- 1,045 people
- Sponsor
- University Hospital, Angers
Non-alcoholic Fatty Liver Disease
Urinary Metabonomics of Two Major Patterns of NAFLD
NAFLD(non-alcoholic fatty liver disease, NAFLD) is a common liver disease with a high morbidity which seriously influence people's health.
- Trial name
- NCT02077283
- Where
- China
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- ShuGuang Hospital
T2DM With NAFLD
AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.
This is a phase I/IIa, randomized, single-blind, placebo-controlled, multiple-ascending dose study conducted at a single site. The study plans to include up to approximately 46 evaluable subjects with Type 2 Diabetes Mellitus…
- Trial name
- NCT02826525
- Testing
- AZD4076
- Volunteers
- 14 people
- Sponsor
- AstraZeneca
Fatty Liver
Limonene on Regulating Metabolism-related Fatty Liver Disease (MAFLD) and Analysis of TCM Constitution
The prevention and treatment of metabolic-related fatty liver disease (MAFLD) involves many fields in preventive medicine and clinical medicine.
- Trial name
- DL-MAFLD-TCM (NCT04853082)
- Testing
- Limonene capsule
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Hongsheng Tan
Healthy
Study of Multiple Oral Doses of PF-06835919 in Healthy Adult Japanese Participants
This is a Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of multiple oral doses of PF-06835919 in healthy adult Japanese participants.
- Trial name
- NCT04427917
- Testing
- PF-06835919
- Where
- Belgium
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pfizer
Non-alcoholic Fatty Liver Disease
Prospective Cohort Study in Patients With NAFLD
To assess the importance of intracellular signalling pathways and its deregulation in adiposity and diabetes-related insulin resistance, liver tissue samples of patients suffering from non-alcoholic fatty liver disease (NAFLD)…
- Trial name
- NCT00575133
- Where
- Switzerland
- Volunteers
- 150 people
- Sponsor
- University of Zurich
Nonalcoholic Fatty Liver Disease
Treatment of Nonalcoholic Fatty Liver Disease With Probiotics and Prebiotics
The investigators' aim is to determine whether probiotic and prebiotic treatment plus lifestyle advice is more effective in reducing hepatic fat content than lifestyle advice alone in patients with Nonalcoholic Fatty Liver…
- Trial name
- NCT00870012
- Testing
- Lepicol probiotic & prebiotic formula, Simple lifestyle advice
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese University of Hong Kong
NASH - Nonalcoholic Steatohepatitis
Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers
This is a non-randomized, 2-part, open-label, drug-drug interaction (DDI) study to evaluate the effect of concomitant administration of fluconazole or quinidine on the pharmacokinetics and safety of EDP-305 in healthy human…
- Trial name
- NCT03610945
- Testing
- Fluconazole, Quinidine, EDP-305
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Steatosis, Liver, Type2 Diabetes
Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.
SGLT2 antagonists and GLP1 agonists are used since a relatively short period as second line therapy if indicated and are well tolerated by patients featuring low risk of hypoglycaemia in comparison to insulin or other oral…
- Trial name
- EXENDA (NCT03007329)
- Testing
- Exenatide, Dapagliflozin
- Where
- Austria
- Volunteers
- 34 people
- Sponsor
- Medical University of Vienna
NASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver Disease
Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric Surgery
The purpose of this study is to evaluate imaging and other biomarkers of non-alcoholic fatty liver disease before and after bariatric surgery.
- Trial name
- BARI (NCT03294850)
- Testing
- Bariatric surgery, HepQuant SHUNT Dual Cholate Liver Diagnostic Kit
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.